New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
12:20 EDTFTNT, CRUS, TPX, FIO, ISISStocks with increasing option volume; ISIS TPX FTNT FIO CRUS
News For ISIS;TPX;FTNT;FIO;CRUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
11:08 EDTFTNTSony Pictures hack highlights need for more IT security spending, analyst says
Subscribe for More Information
10:07 EDTTPXHigh option volume stocks
Subscribe for More Information
November 25, 2014
07:49 EDTTPXTempur Sealy share gains likely to continue, says BofA/Merrill
BofA/Merrill said Tempur's North American sales have been impressive and gained share in Q3. The firm expects Tumpur to report earnings growth above the industry for the next two years and sees further upside from greater-than-expected Sealy synergies and debt pay down. Shares are Buy rated with a $61 price target.
07:09 EDTISISIsis Pharmaceuticals initiates pivotal Phase 3 study evaluating ISIS-SMN
Subscribe for More Information
November 20, 2014
11:05 EDTFTNTStephens hosts a conference call with Fortinet
Conference call with CEO Xie and CFO Del Matto is being held on November 21 at 2 pm.
07:24 EDTISISGoldman to hold a conference
Subscribe for More Information
07:19 EDTFTNTUBS to hold a conference
Subscribe for More Information
06:40 EDTISISIsis Pharmaceuticals price target raised to $62 from $53 at Piper Jaffray
Subscribe for More Information
November 18, 2014
15:48 EDTISISGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
November 17, 2014
16:43 EDTTPXTempur Sealy appoints Jay Spenchian as Chief Marketing Officer
Subscribe for More Information
06:48 EDTFTNTState Department hacked, NY Times reports
Subscribe for More Information
November 14, 2014
16:52 EDTTPXGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
15:41 EDTISISIsis Pharmaceuticals management to meet with Piper Jaffray
Meeting to be held in Kansas City, MO on November 18 hosted by Piper Jaffray.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use